Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey Liveringhouse, Bradford A. Perez, Gretchen V. MacMillan et al.|International Journal of Radiation Oncology*Biology*Physics|2023Cited by 18
A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary reportS. Kim, Andrew S. Brohl, Nikhil I. Khushalani et al.|Annals of Oncology|2019Cited by 5
LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinomaS. Kim, Andrew S. Brohl, Evan Wuthrick et al.|Annals of Oncology|2022Cited by 0